StoryTest
Retro doses first participants in placebo-controlled Phase 1 trial of RTR242 in healthy volunteers in Adelaide, Australia
Retro BiosciencesRTR242 (autophagy)
Retro dosed the first participant in a randomised, double-blind, placebo-controlled Phase 1 trial of RTR242 in healthy volunteers. RTR242 is an oral small molecule designed to restore lysosomal function, the cell's recycling system that declines with age.
- Phase 1 trial in Adelaide, Australia enrolls healthy volunteers to assess safety, tolerability and exploratory autophagy biomarkers.
- RTR242 aims to restore acidic lysosomal environment needed for breaking down damaged proteins and cellular waste.
- Autophagy machinery declines with age; trial will generate first human signals of biological mechanism.